Stockreport

Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mu...

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF CAMBRIDGE, Mass., June 5, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patie [Read more]